Expert Review of Vaccines

Papers
(The TQCC of Expert Review of Vaccines is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States194
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey98
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China95
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant 91
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy87
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?77
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic69
Indirect protection from rotavirus vaccines: a systematic review69
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response61
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review58
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness52
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era52
The important lessons lurking in the history of meningococcal epidemiology50
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection45
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-202044
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis41
Microarray patches: scratching the surface of vaccine delivery41
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China41
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany40
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo39
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children39
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom38
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study38
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus36
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China36
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays35
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis35
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women35
Vaccines against leishmaniasis: using controlled human infection models to accelerate development34
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China33
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond33
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above33
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy32
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis32
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion31
Immunization in pregnancy to protect pregnant people and their newborns against COVID-1931
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment30
Cost-effectiveness of cell-based influenza vaccine in France30
Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States29
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis27
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative27
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany27
TAK-003: development of a tetravalent dengue vaccine26
Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America25
Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines25
COVID-19 vaccination and mask wearing behaviors in the United States, August 2020 - June 202125
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan25
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination25
Looking to the future: is a universal coronavirus vaccine feasible?25
COVID-19 vaccine trials and sex-disaggregated data25
In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers25
Self-controlled case series design in vaccine safety: a systematic review24
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China24
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China24
Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges24
Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia24
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population23
Travelers’ preferences for tick-borne encephalitis vaccination22
COVID-19 vaccination in pregnant and lactating women: a systematic review22
Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru21
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems21
Adjuvant system AS01: from mode of action to effective vaccines20
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect20
Anti-neuraminidase immunity in the combat against influenza20
Vaccines against mpox: MVA-BN and LC16m820
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o19
Vaccination policies for dentists and other dental professionals in Europe: a systematic report19
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine19
Innovation and immunization program management: traceability and quality in Latin America and the Caribbean, laying the groundwork for a regional action plan19
An instrument to measure psychosocial determinants of health care professionals’ vaccination behavior: Validation of the Pro-VC-Be questionnaire19
Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China19
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination18
Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis18
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children18
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines18
Suspended cell lines for inactivated virus vaccine production17
A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan17
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks17
Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009–201917
Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease17
Immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories17
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States17
Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review17
The durability of vaccine-induced protection: an overview17
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study17
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study17
Impact of rotavirus vaccination on diarrheal disease burden of children in South America17
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome16
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?16
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review16
Next generation live-attenuated influenza vaccine platforms16
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine16
Estimating the time required to reach HPV vaccination targets across Europe16
A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK16
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination16
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine15
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study15
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs15
Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era14
Public health impact and return on investment of the pediatric immunization program in Poland14
COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey14
Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?14
Expert review on global real-world vaccine effectiveness against SARS-CoV-214
Have mRNA vaccines sentenced DNA vaccines to death?14
Eyedrop vaccination: an immunization route with promises for effective responses to pandemics14
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses14
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older14
Making COVID-19 mRNA vaccines accessible: challenges resolved14
Development of a recombinant vaccine against human onchocerciasis14
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study14
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza13
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella13
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients13
Lymphatic filariasis vaccine development: neglected for how long?13
Health behaviors are largely not predictive of adverse events following influenza vaccination13
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions13
Correspondence on ‘Herpes Zoster and Simplex reactivation following COVID-19 vaccination’13
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution13
COVID-19 and vaccination: myths vs science13
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice13
0.082619905471802